BioArctic

BioArctic Capital Intensity

The Capital Intensity Ratio of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 128.82 %. In the previous year, Capital Intensity Ratio was 431.97 % — a change of -70.18% (lower).

Capital Intensity

128.82 %

YoY

-70.18%

Last updated:

Capital Intensity Ratio of BioArctic is 2025 128.82 % . Capital Intensity Ratio of BioArctic was 2024 431.97 % . It decreases by -70.18% lower compared to the previous year.

The BioArctic Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
195.11 SEK
Jan 1, 2019
419.96 SEK
Jan 1, 2020
1,684.62 SEK
Jan 1, 2021
3,878.55 SEK
Jan 1, 2022
375.97 SEK
Jan 1, 2023
192.55 SEK
Jan 1, 2024
431.97 SEK
Jan 1, 2025
128.82 SEK
The BioArctic Capital Intensity history
YEARCapital IntensityYoY
128.82 %-70.18%
431.97 %+124.35%
192.55 %-48.79%
375.97 %-90.31%
3,878.55 %+130.23%
1,684.62 %+301.14%
419.96 %+115.24%
195.11 %-75.93%
810.54 %+20.91%
670.35 %+112.56%
315.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Capital Intensity Ratio of BioArctic is 128.82 % in 2025.

Capital Intensity Ratio of BioArctic changed from 431.97 % to 128.82 %, representing a -70.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio BioArctic since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioArctic

All Key Metrics — BioArctic